BRCA1 and ovarian carcinoma: Supportive of this, patients with BRCA1/2 wild-type platinum-sensitive ovarian carcinomas with high degrees of LOH responded better to rucaparib than patients with low degrees of LOH in the ARIEL2 phase 2 clinical trial (NCT01891344) [33], demonstrating the potential of PARP inhibition to be extended beyond BRCA1/2 mutated tumors.